2023 ASH Pregnancy Update Slides Etavopivat treatment Low molecular weight heparin versus a standard pregnancy care for women with recurrent miscarriage Okay, so this first abstract let’s talk about low molecular weight heparin versus a standard pregnancy care for women with recurrent miscarriage age and inherited thrombophilia. ALIFE2, which was an open-label phase three randomized control trial. As studies have shown an association between re. Carriages and inherited thrombophilia. And usually we just put the patient on ox if they have miscarriages, plus the proven thrombophilia. And then we go until the end of the pregnancy with ox. And…
Author: Editor
2023 ASH AML Updates [Slides] – Kiran Naqvi MD – MOASC Acute myeloid leukemia updates from our recent ASH from 2022 By Kiran Naqvi, MD Acute myeloid leukemia. These are the updates from our recent ASH from 2022 Acute myeloid leukemia. These are the updates from our recent ASH from 2022. So moving on. The first abstract that I wanted to talk about was an acute promyelocytic leukemia standard risk not high risk where patient, this is a Chinese study, sorry. And. What they did was they compared ECTRA in combination with an oral formation of arsenic known as RGA Indigo.…
Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson, MD What did the phase 3 Transform study show in patients with relapsed or refractory large B-cell lymphoma (LBCL)? So with this ASH (American Society of Hematology) meeting, I was honored to present the primary analysis of the Transform trial, which is a randomized phase 3 trial comparing Lisocabtagene Maraleucel (liso-cel), an anti CD19 CAR T-cell product, with the standard of care as second line therapy in patients with relapsed or refractory large B-cell lymphomas. We specifically looked at patients with primary refractory disease…
iFrame is not supported! Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson, MD What did the phase 3 Transform study show in patients with relapsed or refractory large B-cell lymphoma (LBCL)? So with this ASH (American Society of Hematology) meeting, I was honored to present the primary analysis of the Transform trial, which is a randomized phase 3 trial comparing Lisocabtagene Maraleucel (liso-cel), an anti CD19 CAR T-cell product, with the standard of care as second line therapy in patients with relapsed or refractory large B-cell lymphomas. We specifically looked at patients…
Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson, MD What did the phase 3 Transform study show in patients with relapsed or refractory large B-cell lymphoma (LBCL)? So with this ASH (American Society of Hematology) meeting, I was honored to present the primary analysis of the Transform trial, which is a randomized phase 3 trial comparing Lisocabtagene Maraleucel (liso-cel), an anti CD19 CAR T-cell product, with the standard of care as second line therapy in patients with relapsed or refractory large B-cell lymphomas. We specifically looked at patients with primary refractory disease…
MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with MRD? So the study that we have conducted or we’re currently conducting is really a prospective trial. And what we’re trying to do is take patients who have shown to have a durable, deep response to treatment for their myeloma and who are on maintenance therapy and see if they are able to stop their treatment, and then what happens after that happens. And so we’re really relying on MRD (minimal residual disease) testing or MRD (minimal residual disease) technology.…
iFrame is not supported! MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with MRD? So the study that we have conducted or we’re currently conducting is really a prospective trial. And what we’re trying to do is take patients who have shown to have a durable, deep response to treatment for their myeloma and who are on maintenance therapy and see if they are able to stop their treatment, and then what happens after that happens. And so we’re really relying on MRD (minimal residual disease) testing or MRD…
MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with MRD? So the study that we have conducted or we’re currently conducting is really a prospective trial. And what we’re trying to do is take patients who have shown to have a durable, deep response to treatment for their myeloma and who are on maintenance therapy and see if they are able to stop their treatment, and then what happens after that happens. And so we’re really relying on MRD (minimal residual disease) testing or MRD (minimal residual disease) technology.…
Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated safety run-in results show for patients with High-Risk Smoldering Multiple Myeloma? We presented in the American Society of Hematology (ASH). Several abstracts related to MGUS and smoldering multiple myeloma. Some of them about risk stratification, who should be treated for smoldering myeloma because we know that many people are diagnosed with MGUS and smoldering myeloma, but not everyone will to active disease. So we need to be very selective in understanding better who should be treated for the disease and…
iFrame is not supported! Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated safety run-in results show for patients with High-Risk Smoldering Multiple Myeloma? We presented in the American Society of Hematology (ASH). Several abstracts related to MGUS and smoldering multiple myeloma. Some of them about risk stratification, who should be treated for smoldering myeloma because we know that many people are diagnosed with MGUS and smoldering myeloma, but not everyone will to active disease. So we need to be very selective in understanding better who should be treated…
Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated safety run-in results show for patients with High-Risk Smoldering Multiple Myeloma? We presented in the American Society of Hematology (ASH). Several abstracts related to MGUS and smoldering multiple myeloma. Some of them about risk stratification, who should be treated for smoldering myeloma because we know that many people are diagnosed with MGUS and smoldering myeloma, but not everyone will to active disease. So we need to be very selective in understanding better who should be treated for the disease and…
Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment plans. Are you ready to incorporate these emerging therapies into your treatment plans? Dr. Sameer Parikh discusses these emerging BTK inhibitors for CLL / SLL, how they differ from current approaches, and future opportunities to introduce these therapies into your clinical decisions. Hear a patient case and the question and answer portion from this visiting lecture series. This activity also includes downloadable slides from the series to improve care for your patients with CLL/SLL. To claim credit: https://www.achlcme.org/btk-inhibitors-cll-sll-onctube
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is a Anti-CD38? And How can Anti-CD38 help patients with Relapsed/Refractory Multiple Myeloma (RRMM)? This study that we presented at this year’s ASH (American Society of Hematology) meeting was entitled, Enduring Responses After One Year Fixed Duration Cevostamab Therapy in Patients With Relapsed And Refractory Of Multiple Myeloma Early Experience From A Phase 1 study. Now, the bispecific antibodies are an exciting new field in myeloma, with the recent approval of Teclistamab and the recent filing of Talquetamab we recognize that they’re gonna be…
iFrame is not supported! Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is a Anti-CD38? And How can Anti-CD38 help patients with Relapsed/Refractory Multiple Myeloma (RRMM)? This study that we presented at this year’s ASH (American Society of Hematology) meeting was entitled, Enduring Responses After One Year Fixed Duration Cevostamab Therapy in Patients With Relapsed And Refractory Of Multiple Myeloma Early Experience From A Phase 1 study. Now, the bispecific antibodies are an exciting new field in myeloma, with the recent approval of Teclistamab and the recent filing of Talquetamab we recognize…
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is a Anti-CD38? And How can Anti-CD38 help patients with Relapsed/Refractory Multiple Myeloma (RRMM)? This study that we presented at this year’s ASH (American Society of Hematology) meeting was entitled, Enduring Responses After One Year Fixed Duration Cevostamab Therapy in Patients With Relapsed And Refractory Of Multiple Myeloma Early Experience From A Phase 1 study. Now, the bispecific antibodies are an exciting new field in myeloma, with the recent approval of Teclistamab and the recent filing of Talquetamab we recognize that they’re gonna be…
Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL By Craig Sauter, MD How does Pembrolizumab (MK-3475), also known as Pembro, after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma help? So this was a multi-side phase 2 single armed study. Originally designed with multiple cohorts looking at the role of Pembrolizumab (Pembro) maintenance, following high dose chemotherapy and autologous stem cell transplant in consolidation for various lymphomas. The abstract presented at ASH was cohort C, which is looking specifically at the patient’s proceeding to consolidative autonomous transplant for peripheral T-cell lymphomas. So this was a…
iFrame is not supported! Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL By Craig Sauter, MD How does Pembrolizumab (MK-3475), also known as Pembro, after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma help? So this was a multi-side phase 2 single armed study. Originally designed with multiple cohorts looking at the role of Pembrolizumab (Pembro) maintenance, following high dose chemotherapy and autologous stem cell transplant in consolidation for various lymphomas. The abstract presented at ASH was cohort C, which is looking specifically at the patient’s proceeding to consolidative autonomous transplant for peripheral T-cell lymphomas.…
Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL By Craig Sauter, MD How does Pembrolizumab (MK-3475), also known as Pembro, after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma help? So this was a multi-side phase 2 single armed study. Originally designed with multiple cohorts looking at the role of Pembrolizumab (Pembro) maintenance, following high dose chemotherapy and autologous stem cell transplant in consolidation for various lymphomas. The abstract presented at ASH was cohort C, which is looking specifically at the patient’s proceeding to consolidative autonomous transplant for peripheral T-cell lymphomas. So this was a…
MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib By Abdulraheem Yacoub, MD What were the results of the MPN (myeloproliferative neoplasm) Study of the add-on of Parsaclisib to Ruxolitinib therapy? At the American Society of Hematology (ASH) 2022 in New Orleans, I had the opportunity to present the final safety and efficacy results of the add-on Parsaclisib study in patients with myelofibrosis and suboptimal response. This is the final results of a phase 2 study. Ruxolitinib has been approved for myelofibrosis, for clinical benefits. That includes splenic reduction, symptom improvement, and survival advantage. However, some patients manifest a suboptimal…
iFrame is not supported! MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib By Abdulraheem Yacoub, MD What were the results of the MPN (myeloproliferative neoplasm) Study of the add-on of Parsaclisib to Ruxolitinib therapy? At the American Society of Hematology (ASH) 2022 in New Orleans, I had the opportunity to present the final safety and efficacy results of the add-on Parsaclisib study in patients with myelofibrosis and suboptimal response. This is the final results of a phase 2 study. Ruxolitinib has been approved for myelofibrosis, for clinical benefits. That includes splenic reduction, symptom improvement, and survival advantage. However, some…
MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib By Abdulraheem Yacoub, MD What were the results of the MPN (myeloproliferative neoplasm) Study of the add-on of Parsaclisib to Ruxolitinib therapy? At the American Society of Hematology (ASH) 2022 in New Orleans, I had the opportunity to present the final safety and efficacy results of the add-on Parsaclisib study in patients with myelofibrosis and suboptimal response. This is the final results of a phase 2 study. Ruxolitinib has been approved for myelofibrosis, for clinical benefits. That includes splenic reduction, symptom improvement, and survival advantage. However, some patients manifest a suboptimal…
PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial By Srdan Verstovsek, MD, PhD What were the results of the PTG-300 Verify phase 3 clinical trial in polycythemia vera patients? The study (design) of interest is the primary session report of the development of new antibody, and that antibody is against a mutated calreticulin. Now, what is the mutated calreticulin? In all the patients with myeloproliferative, neoplasms being ET or PV (diagnosis polycythemia vera) or myelofibrosis, there is a hyperactivity of intercellular signal. … JTA pathway, and this is because of our CE mutations in about 30% of the…
iFrame is not supported! PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial By Srdan Verstovsek, MD, PhD What were the results of the PTG-300 Verify phase 3 clinical trial in polycythemia vera patients? The study (design) of interest is the primary session report of the development of new antibody, and that antibody is against a mutated calreticulin. Now, what is the mutated calreticulin? In all the patients with myeloproliferative, neoplasms being ET or PV (diagnosis polycythemia vera) or myelofibrosis, there is a hyperactivity of intercellular signal. JTA pathway, and this is because of our CE mutations in…
PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial By Srdan Verstovsek, MD, PhD What were the results of the PTG-300 Verify phase 3 clinical trial in polycythemia vera patients? The study (design) of interest is the primary session report of the development of new antibody, and that antibody is against a mutated calreticulin. Now, what is the mutated calreticulin? In all the patients with myeloproliferative, neoplasms being ET or PV (diagnosis polycythemia vera) or myelofibrosis, there is a hyperactivity of intercellular signal. JTA pathway, and this is because of our CE mutations in about 30% of the…
For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar Georgetown University Hospital, talks about Managing Treatment Toxicities: A Practical Approach. In this video, Dr. Chul Kim discusses possible side effects from ROS1-TKIs, including dysgeusia, and neurologic events. We thank our sponsors for this year’s support! #novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar Georgetown University Hospital, talks about Managing Treatment Toxicities: A Practical Approach. In this video, Dr. Chul Kim analyzes possible side effects of ALK-TKIs, including hypercholesterolemia, pulmonary events, and cognitive effects. We thank our sponsors for this year’s support! #novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar Georgetown University Hospital, talks about Managing Treatment Toxicities: A Practical Approach. In this video, Dr. Chul Kim examines two rare side effects of EGFR-TKIs: pneumonitis and cardiotoxicity We thank our sponsors for this year’s support! #hormonetherapy #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar Georgetown University Hospital, talks about Managing Treatment Toxicities: A Practical Approach. In this video, Dr. Chul Kim discusses management of two possible side effects of EGFR-TKIs: stomatitis and diarrhea. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar Georgetown University Hospital, talks about Managing Treatment Toxicities: A Practical Approach. In this video, Dr. Chul Kim discusses dermatologic side effects of EGFR TKIs, including pruritis, xerosis, paronychia, and acneiform rash. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School; Thoracic Oncologist, Lowe Center for Thoracic Oncology, Dana Farber Cancer Insititute, discusses the Management of Oligoprogression in Mutated Advanced NSCLC. In this video, Dr. Narjust Florez examines oligoprogression specifically in EGFR Mutant NSCLC. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School; Thoracic Oncologist, Lowe Center for Thoracic Oncology, Dana Farber Cancer Insititute, discusses the Management of Oligoprogression in Mutated Advanced NSCLC. In this video, Dr. Narjust Florez discusses how oligoprogression is treated, focusing on local therapies. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School; Thoracic Oncologist, Lowe Center for Thoracic Oncology, Dana Farber Cancer Insititute, discusses the Management of Oligoprogression in Mutated Advanced NSCLC.In this video, Dr. Narjust Florez discusses how to identify oligoprogression of disease.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School; Thoracic Oncologist, Lowe Center for Thoracic Oncology, Dana Farber Cancer Insititute, discusses the Management of Oligoprogression in Mutated Advanced NSCLC. In this video, Dr. Narjust Florez explains what defines oligoprogression of disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can Pembro (MK-3475) help patients with with -cell non-hodgkin lymphoma? I’m excited about this phase 2 Pembro (MK-3475) study, Pembrolizumab after autologous stem cell transplant in patients with T-cell lymphoma. As most rare for T-cell lymphomas have a poor prognosis and it’s really hard for developing new therapies given the heterogeneous nature of this disease and currently high dose chemotherapy and consolidation with an autologous stem-cell transplant is recommended in first remission. And however, at the moment we also do not have any options for…
iFrame is not supported! Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can Pembro (MK-3475) help patients with with -cell non-hodgkin lymphoma? I’m excited about this phase 2 Pembro (MK-3475) study, Pembrolizumab after autologous stem cell transplant in patients with T-cell lymphoma. As most rare for T-cell lymphomas have a poor prognosis and it’s really hard for developing new therapies given the heterogeneous nature of this disease and currently high dose chemotherapy and consolidation with an autologous stem-cell transplant is recommended in first remission. And however, at the moment we also do not…
Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can Pembro (MK-3475) help patients with with -cell non-hodgkin lymphoma? I’m excited about this phase 2 Pembro (MK-3475) study, Pembrolizumab after autologous stem cell transplant in patients with T-cell lymphoma. As most rare for T-cell lymphomas have a poor prognosis and it’s really hard for developing new therapies given the heterogeneous nature of this disease and currently high dose chemotherapy and consolidation with an autologous stem-cell transplant is recommended in first remission. And however, at the moment we also do not have any options for…
MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do for patients with Newly Diagnosed Multiple Myeloma (NDMM) and does that include next-generation sequencing? So we adopted a institutional strategy to start do quadruplet induction therapy with a 4 drug-based induction for multiple myeloma from the March of 2020. And since UAB is the only transplant center in the state of Alabama, we have entire state of population who are transplant eligible and are nearly diagnosed with multiple myeloma referred to UAB for transplant. So we have an established communication…
iFrame is not supported! MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do for patients with Newly Diagnosed Multiple Myeloma (NDMM) and does that include next-generation sequencing? So we adopted a institutional strategy to start do quadruplet induction therapy with a 4 drug-based induction for multiple myeloma from the March of 2020. And since UAB is the only transplant center in the state of Alabama, we have entire state of population who are transplant eligible and are nearly diagnosed with multiple myeloma referred to UAB for transplant. So we…
MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do for patients with Newly Diagnosed Multiple Myeloma (NDMM) and does that include next-generation sequencing? So we adopted a institutional strategy to start do quadruplet induction therapy with a 4 drug-based induction for multiple myeloma from the March of 2020. And since UAB is the only transplant center in the state of Alabama, we have entire state of population who are transplant eligible and are nearly diagnosed with multiple myeloma referred to UAB for transplant. So we have an established communication…
PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer How can a PI3Kα inhibitor help patients suffering with breast cancer? The company that I represent is Scorpion Therapeutics, our focus is on elevating the entire game for precision oncology, so using targeted molecules that go after mutations and cancer and optimize outcomes for patients. So we call that Precision Oncology 2.0, now what we’re presenting here at SABCS is basically data on our lead compound, a PI3Kα inhibitor that is mutation selective. We call it STX-478, that has shown very high level, a selectivity against specific (oncogenic) mutations…
iFrame is not supported! PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer How can a PI3Kα inhibitor help patients suffering with breast cancer? The company that I represent is Scorpion Therapeutics, our focus is on elevating the entire game for precision oncology, so using targeted molecules that go after mutations and cancer and optimize outcomes for patients. So we call that Precision Oncology 2.0, now what we’re presenting here at SABCS is basically data on our lead compound, a PI3Kα inhibitor that is mutation selective. We call it STX-478, that has shown very high level, a selectivity against…
PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer How can a PI3Kα inhibitor help patients suffering with breast cancer? The company that I represent is Scorpion Therapeutics, our focus is on elevating the entire game for precision oncology, so using targeted molecules that go after mutations and cancer and optimize outcomes for patients. So we call that Precision Oncology 2.0, now what we’re presenting here at SABCS is basically data on our lead compound, a PI3Kα inhibitor that is mutation selective. We call it STX-478, that has shown very high level, a selectivity against specific (oncogenic) mutations…
Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results show for patients with HR+/HER2- metastatic breast cancer (MBC)? Sacituzumab Govitecan is a first in class Trop-2-directed antibody-drug conjugates linked to a Topoisomerase 1 inhibitor. The active metabolite of Irinotecan SN-38 Sacituzumab is already FDA approved for the treatment of metastatic Triple-negative breast cancer (TNBC) in patients who’ve received at least one line of prior chemotherapy based on data from the ASCENT trial. Where it showed improvement in progression-free and overall survival compared to chemotherapy of physician choice. In an initial phase one Umbrella…
iFrame is not supported! Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results show for patients with HR+/HER2- metastatic breast cancer (MBC)? Sacituzumab Govitecan is a first in class Trop-2-directed antibody-drug conjugates linked to a Topoisomerase 1 inhibitor. The active metabolite of Irinotecan SN-38 Sacituzumab is already FDA approved for the treatment of metastatic Triple-negative breast cancer (TNBC) in patients who’ve received at least one line of prior chemotherapy based on data from the ASCENT trial. Where it showed improvement in progression-free and overall survival compared to chemotherapy of physician choice. In an…
Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results show for patients with HR+/HER2- metastatic breast cancer (MBC)? Sacituzumab Govitecan is a first in class Trop-2-directed antibody-drug conjugates linked to a Topoisomerase 1 inhibitor. The active metabolite of Irinotecan SN-38 Sacituzumab is already FDA approved for the treatment of metastatic Triple-negative breast cancer (TNBC) in patients who’ve received at least one line of prior chemotherapy based on data from the ASCENT trial. Where it showed improvement in progression-free and overall survival compared to chemotherapy of physician choice. In an initial phase one Umbrella…
ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial What can this PROTAC estrogen receptor degrader do for patients with metastatic breast cancer? ARV-471 is a PROTAC targeted protein degrader, so unlike surges, what it does is it tar targets the estrogen receptor and it hijacks. The cell zone machinery for degrading proteins the ubiquitous proteasome system. So this is a very potent ER degrader and the trial that was presented this morning was the VERITAC phase 2 study. And this is a study that was evaluating 2 different doses that were determined based on our phase one.…
iFrame is not supported! ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial What can this PROTAC estrogen receptor degrader do for patients with metastatic breast cancer? ARV-471 is a PROTAC targeted protein degrader, so unlike surges, what it does is it tar targets the estrogen receptor and it hijacks. The cell zone machinery for degrading proteins the ubiquitous proteasome system. So this is a very potent ER degrader and the trial that was presented this morning was the VERITAC phase 2 study. And this is a study that was evaluating 2 different doses that were determined based…
ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial What can this PROTAC estrogen receptor degrader do for patients with metastatic breast cancer? ARV-471 is a PROTAC targeted protein degrader, so unlike surges, what it does is it tar targets the estrogen receptor and it hijacks. The cell zone machinery for degrading proteins the ubiquitous proteasome system. So this is a very potent ER degrader and the trial that was presented this morning was the VERITAC phase 2 study. And this is a study that was evaluating 2 different doses that were determined based on our phase one.…
For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis in Cancer. In this video, Dr. Medhavi Gupta reiterates the importance of breast cancer screening in detection and treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Medhavi Gupta examines how treatment can look for patients diagnosed with breast cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.